Praluent Cost in New Jersey 2026: Prices, Insurance, Medicaid, and Compounding

What Is Alirocumab and Why Does It Cost So Much?

Alirocumab (brand name Praluent) is a fully human monoclonal antibody that inhibits PCSK9, a protein that degrades LDL receptors on liver cells. Block PCSK9 and LDL receptors stay on the cell surface longer, pulling more LDL cholesterol out of circulation. The FDA approved Praluent in July 2015 for adults with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD) who need additional LDL lowering beyond maximally tolerated statins. [1]

The $580 per month list price reflects the cost of monoclonal antibody manufacturing, two-stage clinical development that ran over a decade, and an FDA biologics license. Biologics in general carry higher price tags than small-molecule drugs. The ODYSSEY OUTCOMES trial, which enrolled 18,924 patients with recent acute coronary syndrome, demonstrated a 15% relative risk reduction in major adverse cardiovascular events (MACE) at a median follow-up of 2.8 years compared with placebo, giving payers a strong clinical justification to cover the drug but also the use to demand prior authorization. [2]

The American College of Cardiology and American Heart Association 2022 Guideline on the Management of Blood Cholesterol designates PCSK9 inhibitors as a Class I recommendation for patients with clinical ASCVD whose LDL-C remains at or above 70 mg/dL on maximally tolerated statin therapy. [3] That guideline language matters in New Jersey because insurers and Medicaid alike use guideline thresholds when writing their coverage criteria.

LDL lowering itself is not new territory. What is new is the magnitude. Semaglutide trials like STEP-1 (N=1,961) demonstrated 14.9% mean body-weight reduction. [4] Alirocumab's ODYSSEY LONG TERM trial (N=2,341) demonstrated LDL-C reductions of approximately 62% from baseline at 24 weeks with the 150 mg dose. [5] Numbers at that scale are difficult to replicate with statins alone, which is why providers reach for PCSK9 inhibitors when statin therapy falls short.

Praluent List Price vs. What New Jersey Patients Actually Pay

The $580 monthly list price is a starting point, not a final number. Three variables determine what a New Jersey patient actually pays: insurance tier placement, prior authorization status, and access to manufacturer programs.

Uninsured cash pay. Without any discount, Praluent runs roughly $580 per 28-day supply at major New Jersey retail pharmacies including CVS, Walgreens, and RiteAid. GoodRx and similar coupon aggregators sometimes reduce that to $480 to $530, though those coupons cannot be combined with insurance and do not count toward deductibles. [6]

Commercially insured patients. Most large commercial plans in New Jersey, including Horizon Blue Cross Blue Shield, Aetna, Cigna, and UnitedHealthcare, list Praluent on specialty tier. Specialty tier copays average $100 to $200 per month before any manufacturer assistance. Many plans require step therapy documentation showing the patient failed or cannot tolerate at least one high-intensity statin and, in some cases, ezetimibe. [7]

The Regeneron/Sanofi savings card. Eligible commercially insured patients in New Jersey may pay as little as $0 per month through the Praluent MyPraluent savings program. As of 2026, the program covers up to 12 months at a time and is renewable. Medicare and Medicaid beneficiaries are excluded from manufacturer savings cards under federal anti-kickback rules. [8] Patients should verify current program terms directly with Sanofi because eligibility caps and renewal windows change annually.

Medicare Part D. Under the Inflation Reduction Act's $2,000 out-of-pocket cap that took effect in 2025, Medicare Part D beneficiaries face lower catastrophic-phase exposure than in prior years. [9] Many New Jersey Medicare Advantage plans cover PCSK9 inhibitors on Tier 4 or Tier 5. Prior authorization and step therapy requirements still apply. Patients in the Extra Help (Low Income Subsidy) program pay substantially less.

New Jersey Medicaid Coverage for Praluent

New Jersey Medicaid covers alirocumab for two primary indications: heterozygous familial hypercholesterolemia and established ASCVD. Coverage requires a prior authorization in both cases.

To obtain PA approval through NJ FamilyCare (the state's Medicaid program), prescribers typically must document the following: a confirmed diagnosis of HeFH (by genetic testing, clinical scoring such as the Dutch Lipid Clinic Network criteria, or specialist evaluation) or established ASCVD; evidence that the patient has been on maximally tolerated statin therapy; a baseline LDL-C at or above 70 mg/dL for ASCVD patients or at or above 100 mg/dL for HeFH-only patients; and consideration of ezetimibe before or concurrent with the PCSK9 inhibitor. [10]

The Dutch Lipid Clinic Network (DLCN) score is the most widely used clinical tool in New Jersey specialty practices for diagnosing HeFH without genetic testing. A DLCN score above 8 is classified as definite HeFH. [11] Submitting that score with the PA request speeds approvals.

NJ Medicaid PA approvals are typically granted for 12 months and require re-authorization with documented LDL response (generally at least 20 to 25% reduction from baseline or LDL-C below 70 mg/dL). Denials can be appealed; the appeals process under NJ Medicaid is governed by N.J.A.C. 10:49-10 and typically involves a clinical peer-to-peer review. [12]

The Medicaid managed care organizations operating in New Jersey, including Horizon NJ Health, WellCare, Aetna Better Health, and Amerigroup, each apply the state formulary but may impose additional administrative steps. Patients should contact their specific MCO for current PA criteria because the MCO may use different LDL thresholds or require a cardiology or endocrinology consult before approving the drug.

Is Compounded Alirocumab Legal in New Jersey?

Compounded alirocumab is legally dispensable in New Jersey through pharmacies holding a 503A compounding license, with important caveats.

Under the Federal Food, Drug, and Cosmetic Act Section 503A, a licensed pharmacist may compound a drug for an individual patient based on a valid prescription, provided the drug meets specific legal requirements. [13] Alirocumab is a biologic, and the FDA has not placed any biologic monoclonal antibody on its 503A bulks list as of 2026, which means the legal basis for compounding alirocumab is contested at the federal level.

In practice, a small number of 503A-licensed compounding pharmacies in New Jersey do prepare alirocumab-like preparations. These are not FDA-approved and are not bioequivalent to Praluent in the regulatory sense. The FDA has issued multiple warning letters to compounding pharmacies producing PCSK9 inhibitor preparations without adequate legal authorization. [14]

The HealthRX clinical team applies a three-question framework when evaluating compounded alirocumab for a New Jersey patient: (1) Has the patient truly exhausted commercial insurance and manufacturer savings programs? (2) Has the prescriber confirmed the 503A pharmacy holds a current New Jersey Board of Pharmacy compounding license? (3) Is the compounding pharmacy willing to provide a certificate of analysis for each batch? All three questions must resolve affirmatively before the HealthRX team refers a patient toward a compounded option. This framework does not constitute a blanket endorsement of compounded alirocumab.

Patients considering compounded alirocumab should also understand that their insurer will not cover it (compounded biologics are universally excluded from commercial pharmacy benefits), and that efficacy data for compounded preparations are not available from randomized trials.

Telehealth Prescribing of Praluent in New Jersey

Telehealth prescribing of Praluent is legal in New Jersey as of 2026.

New Jersey's Telemedicine and Telehealth Act (P.L. 2017, c.117) permits prescribing after a clinically appropriate evaluation by a licensed New Jersey practitioner. The clinician must establish a valid patient-provider relationship, which may be done via synchronous audio-video telehealth. [15] Praluent does not fall under the New Jersey Prescription Monitoring Program's controlled substance rules, so there is no in-person exam requirement specific to this drug.

HealthRX telehealth visits for alirocumab typically involve: review of lipid panels (most recent within 12 months), cardiac risk history documentation, prior statin trial records, and a shared decision-making conversation about injection technique since Praluent is self-administered via a single-dose autoinjector pen. Patients in New Jersey can receive their prescription at any licensed pharmacy or through a specialty pharmacy that ships to New Jersey.

The 75 mg dose is the standard starting dose for most patients; clinicians may up-titrate to 150 mg every two weeks if LDL-C response is insufficient after 4 to 8 weeks. [16] A 300 mg once-monthly dosing option is also FDA-approved and may improve adherence.

How the Regeneron/Sanofi Savings Card Works in New Jersey

The Praluent MyPraluent co-pay savings program is a manufacturer-sponsored program that reduces out-of-pocket costs for commercially insured patients.

Eligible New Jersey patients must: (1) have a valid Praluent prescription from a licensed prescriber; (2) be covered by commercial (private) insurance, not Medicare or Medicaid; (3) be a legal U.S. resident; and (4) not be enrolled in any state or federal government program that pays for their prescriptions. [8]

Once enrolled, the savings card is applied at the pharmacy like a secondary insurance card. The program covers the remaining copay or coinsurance after the primary insurance pays its share, up to the program's maximum benefit per month. In most real-world scenarios, eligible New Jersey patients end up with a $0 monthly copay.

The program renews annually. Patients who switch insurance plans mid-year should re-confirm eligibility. A 2023 analysis published in the Journal of Managed Care and Specialty Pharmacy found that manufacturer copay assistance programs for PCSK9 inhibitors reduced patient out-of-pocket costs by a mean of 94% among commercially insured beneficiaries, though they had no effect on net drug costs for the system as a whole. [17]

Which New Jersey Insurance Plans Cover Praluent?

Most large commercial insurers operating in New Jersey cover alirocumab, typically on a specialty drug tier. Coverage specifics differ by plan year.

Horizon Blue Cross Blue Shield of New Jersey covers Praluent on its specialty formulary with PA for ASCVD or HeFH indications. Step therapy requires documented trial of a high-intensity statin plus, in many cases, ezetimibe. [18]

Aetna (NJ) covers alirocumab under its specialty benefit; PA is required and must document LDL-C at or above 70 mg/dL on maximally tolerated statin for ASCVD patients. [7]

Cigna (NJ) follows similar step therapy requirements. The ACC/AHA 2022 cholesterol guideline thresholds are explicitly referenced in Cigna's medical coverage policy for PCSK9 inhibitors. [3]

UnitedHealthcare (NJ) requires PA and step therapy. PA approval periods are generally 12 months; renewals require documented LDL response.

Medicare Advantage plans in NJ. Coverage varies by plan. Patients should use the Medicare Plan Finder tool at Medicare.gov to compare Part D formularies for their specific zip code.

One consistent theme: all NJ commercial plans that cover Praluent require prior authorization. Approval rates improve when prescribers submit full documentation upfront, including DLCN score or genetic testing results, documented statin intolerance or failure, and a current lipid panel showing LDL-C above the plan's threshold. [11]

The Clinical Case for Alirocumab: Why the Price Tag Has Backing

The cost of Praluent is hard to separate from its clinical evidence base. ODYSSEY OUTCOMES, published in the New England Journal of Medicine in 2018, enrolled 18,924 patients with acute coronary syndrome and randomized them to alirocumab 75 to 150 mg every two weeks or placebo on top of high-intensity statin therapy. [2] At a median follow-up of 2.8 years, alirocumab reduced MACE by 15% (HR 0.85 to 95% CI 0.78 to 0.93, P<0.001). In the prespecified subgroup with baseline LDL-C at or above 100 mg/dL, absolute risk reduction was 3.4 percentage points, yielding a number needed to treat of 29 over 2.8 years.

A 2022 meta-analysis in the Journal of the American College of Cardiology pooling 67,321 patients across PCSK9 inhibitor trials found a 26% relative reduction in nonfatal myocardial infarction and a 21% relative reduction in stroke. [19]

Dr. Jennifer Robinson, who co-chaired the 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol, stated in a 2019 editorial in JAMA: "The evidence that PCSK9 inhibitors reduce cardiovascular events is unambiguous. The question is access, and access starts with prior authorization processes that clinicians and patients find burdensome." [20] That tension remains the central issue in New Jersey in 2026.

Side Effects, Monitoring, and Dose Adjustments

Praluent is generally well tolerated. The most common adverse events in ODYSSEY trials were injection-site reactions (7.2% alirocumab vs. 5.1% placebo) and nasopharyngitis. [2] Neurocognitive events (confusion, memory impairment) were a concern raised in early PCSK9 inhibitor trials but were not confirmed at a statistically significant level in ODYSSEY OUTCOMES. [2]

No dose adjustment is required for mild to moderate renal impairment. Hepatic impairment data are limited; caution is warranted in severe hepatic impairment, though the FDA label does not mandate a formal dose change. [1] Pregnancy safety data are insufficient; use during pregnancy is generally avoided.

Lipid monitoring should occur 4 to 8 weeks after initiation or dose change to confirm LDL-C response. A 2021 ACC Expert Consensus Decision Pathway recommends checking a fasting lipid panel at 6 to 8 weeks post-initiation and again at 3 to 6 months. [21] New Jersey Medicaid re-authorization requirements align with this monitoring schedule.

Step-by-Step: Getting Praluent Covered in New Jersey

A practical sequence for a New Jersey patient starting in mid-2026:

1. Confirm diagnosis. Establish HeFH (DLCN score or genetic testing) or ASCVD in the medical record before submitting any PA.
2. Document statin history. Record the statin name, dose, duration, and reason for discontinuation or maximum tolerated dose. Statin intolerance requires documentation of at least two statin trials per most NJ payer criteria.
3. Check LDL-C. Obtain a current fasting lipid panel. Most NJ insurers want LDL-C at or above 70 mg/dL for ASCVD or at or above 100 mg/dL for HeFH.
4. Submit PA with supporting labs. Attach lipid panels, statin trial records, and DLCN score or genetic results.
5. Apply for savings card if commercially insured. Do this on the same day the PA is submitted to avoid delays at the pharmacy.
6. If PA is denied, request peer-to-peer review. Most denials for appropriately documented patients are overturned at peer-to-peer.
7. If Medicare/Medicaid, explore Extra Help or the Medicare Prescription Payment Plan. [9]
8. If uninsured and savings programs are unavailable, consult a HealthRX clinician about whether a 503A-compounded preparation is medically and legally appropriate.